Skip to content
Company Analysis

China SXT Pharmaceuticals, Inc. SXTC

A comprehensive view of key metrics, scores, and financial health for China SXT Pharmaceuticals, Inc.

Overview of China SXT Pharmaceuticals, Inc.

SXTC NCM
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech Micro Cap
China SXT Pharmaceuticals, Inc. (SXTC), is a Micro Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $2.57, about 0.0% overvalued vs fair value, -99.1% 1Y return, ranked 1007/1122 in sector.
Metrics Rev Growth -9.7% ROE -22.5% Gross Margin 21.1%
USD 2.57
13.72%
(Delayed)
• Vol 90d: 136.4%
52-Week Range
Market Cap
$11.37M
Enterprise Value
$-8.60M
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Weak
Health
Fair
Efficiency
Weak
Valuation
Weak
Growth
Weak
Profitability
Weak
Health
Fair
Efficiency
Weak
Valuation
Weak
Completeness: 70%
Confidence: 82%
Updated: Mar 8
Top Beats
No strong beats yet

Quick Facts

Website https://www.sxtchina.com
HQ Taizhou
Employees 75
Fiscal year Mar 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$0
$0
$0
Current: $2.57

Engine Room Money Flow™

Micro Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$1.7M
-9.7%%
Gross Profit
$367.4K
-33.7%%
Operating Income (EBIT)
$-2.7M
-4%%
Operating Cash Flow
$-2.3M
-21.6%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Revenue Growth (YoY)
-0.1%
Poor

Revenue declining - patent cliffs or competition

Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
1/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating China SXT Pharmaceuticals, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
33
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
16
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 88% Coverage
Trade-Off Triangle Visualization A ternary plot showing SXTC's balance between Growth (31.0%), Profitability (18.8%), and Safety (50.2%). Growth 31% Safety 50% Profitability 19%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

32th percentile vs peers
33
Key Signals
EPS Growth YoY 79.2% 76p Rev Growth YoY -9.7% 18p Revenue CAGR 3Y -12.5% 14p
Strengths
  • Quick Ratio in top 20% of peers (3.40, 85th percentile)
  • Strong liquidity position vs peers
Risks
  • Rev Growth YoY in bottom 20% of peers (-9.7%)

Profitability

19th percentile vs peers
20
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

52th percentile vs peers
53
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for China SXT Pharmaceuticals, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$-0.12
- - -
- upside
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000